Pharmacophore an International Research Journal
Pharmacophore
Submit Manuscript
Open Access | Published: 2023 - Issue 3

Cytotoxicity of Galantamine Peptide Esters Against Hela Cell Lin Download PDF


, , , ,
Abstract

In this study, the cytotoxic potential of newly synthesized peptide esters of Galantamine, namely GAL-VAL and GAL-LEU, was investigated against the human cervical adenocarcinoma cell line (HeLa) across a range of concentrations spanning from 1.875µM to 30µM. Notably, GAL-LEU demonstrated significant efficacy in suppressing HeLa cells, particularly at a concentration of 30 µM, where it elicited an impressive 86.81% reduction in cell viability. This effect was corroborated by a corresponding index of cell viability of 13.19%. Further analysis revealed that GAL-LEU possessed a substantially lower IC50 value of 23.63 µM compared to GAL-VAL, which exhibited an IC50 value of 31.95µM. These findings highlight the pronounced cytotoxic effects of both esters on the HeLa cell line, with GAL-LEU exhibiting superior antiproliferative potency. The results of this investigation suggest the potential utility of GAL-VAL and GAL-LEU as promising candidates warranting further exploration in cancer therapeutics, particularly in the context of addressing cervical adenocarcinoma.

Cite this article
Vancouver
Tsvetkova D, Vezenkov L, Ivanov T, Danalev D, Kostadinova I. Cytotoxicity of Galantamine Peptide Esters Against Hela Cell Lin. Pharmacophore. 2023;14(3):131-8. https://doi.org/10.51847/E1l0KDSnG1
APA
Tsvetkova, D., Vezenkov, L., Ivanov, T., Danalev, D., & Kostadinova, I. (2023). Cytotoxicity of Galantamine Peptide Esters Against Hela Cell Lin. Pharmacophore, 14(3), 131-138. https://doi.org/10.51847/E1l0KDSnG1

QR code:

Short Link:
Views: 787

Downloads: 62
Quick Access

Associations

Pharmacophore
ISSN: 2229-5402

Copyright © 2024 Pharmacophore. Authors retain copyright of their article if they are accepted for publication.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.